Entries by Ailis Tweed-Kent

Cocoon Biotech Announces CEO, Dr. Ailis Tweed-Kent, Named to Boston Business Journal’s “2017 Women to Watch in Science and Technology” List

BOSTON, Ma, February 16, 2017 – Cocoon Biotech, Inc., a biotechnology company focused on the development of osteoarthritis and other drug-delivery therapies based on its silk protein technology, has announced that Cocoon Founder and CEO, Ailis Tweed-Kent, M.D., has been named by the Boston Business Journal as one of the “2017 Women to Watch in […]

Cocoon Biotech Announces Partnership with Camargo Pharmaceutical Services for Development Programs

  Cambridge, MA  February 2, 2017 – Cocoon Biotech, Inc. (“Cocoon” or the “Company”), is a biotechnology company focused on utilizing its silk protein-based drug delivery technology for the development of formulations to treat osteoarthritis and other conditions for which many patients find existing treatments to be unsatisfactory.  Cocoon announced today that it has entered into […]

Peter Mitchell Named Chief Scientific Officer At Cocoon Biotech

BOSTON, Ma. — Cocoon Biotech, Inc. a biotechnology company focused on the development of osteoarthritis and other drug-delivery therapies based on its silk protein technology, has announced the appointment of Peter Mitchell, Ph.D., as Chief Scientific Officer. Dr. Mitchell brings to the position 25 years of commercial pharmaceutical leadership focused on arthritis and inflammation. To read […]

Spinning Health Solutions from Silk

In 2013, Dr. Ailis Tweed-Kent founded Cocoon Biotech Inc. to come up with a way to treat the actual cause of arthritis, the loss of cartilage in joints. For the therapy, she turned to a biomaterial that has been used for thousands of years: silk. To read more from STAT, visit this page.

Press Release on the Tufts Agreement

Cocoon Biotech to Explore New Treatments for Joint Disease using Silk Biomaterial Platform Developed at Tufts University BOSTON (November 4th, 2014) — Cocoon Biotech today announced that it has entered into exclusive option and sponsored research agreements with Tufts University to explore the commercialization of new treatments for joint disease and arthritis using silk protein […]